Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics

S. K. Dessain(✉), S. P. Adekar, and J. D. Berry

Abstract Native human antibodies are defined as those that arise naturally as the result of the functioning of an intact human immune system. The utility of native antibodies for the treatment of human viral diseases has been established through experience with hyperimmune human globulins. Native antibodies, as a class, differ in some respects from those obtained by recombinant library methods (phage or transgenic mouse) and possess distinct properties that may make them ideal therapeutics.
for human viral diseases. Methods for cloning native human antibodies have been beset by technical problems, yet many antibodies specific for viral antigens have been cloned. In the present review, we discuss native human antibodies and ongoing improvements in cloning methods that should facilitate the creation of novel, potent antiviral therapeutics obtained from the native human antibody repertoire.

1 Introduction: The Native Human Antibody Repertoire and Viral Disease

There is a growing awareness of the utility of and need for human antibody therapeutics for viral diseases (Keller and Stiehm 2000; Oral et al. 2002; Casadevall et al. 2004; Casadevall and Pirofski 2005). Individuals who have recovered from a viral infection, or who have received a therapeutic vaccination, contain a population of antibodies that is capable of contributing to a life-long immunity from the virus. These are defined as “native antibodies,” i.e., antibodies in exactly the configurations created by a functioning, intact human immune system. Native antibodies are most commonly obtained by methods that immortalize primary B cells by hybridoma formation or Epstein-Barr virus (EBV) infection. They are distinct from human or humanized antibodies derived from recombinant DNA or transgenic mouse systems, which may not accurately replicate the complete, wild-type structure of full-length antibodies produced by the human immune system in situ. The native human antibody repertoire has tremendous potential as a source for antiviral antibody therapeutics because it contains definitive immunologic solutions to human viral diseases and is likely to be the safest overall for human clinical use. Polyclonal antibody therapeutics of unselected and disease-specific native immunoglobulins are effective in some clinical situations. These intravenous immunoglobulins (IVIG) are the starting point for exploring the potential value of the native human antibody immunome, but they do not address the vast spectrum of viral diseases for which antibodies have potential therapeutic efficacy. Over the past 25 years, ongoing efforts to improve methods for cloning native human antibodies that can capture and amplify the antiviral capabilities of IVIG have progressed, demonstrating the value of this approach and justifying further exploration. In this review we will consider the history and therapeutic potential of cloned native human antibodies specific for viral illnesses.

2 Intravenous Immunoglobulins for Human Viral Disease

IVIG is the purified population of native human IgG antibodies obtained from blood plasma. The only FDA-approved antiviral use for IVIG is to treat infection by parvovirus B19 (PV B19) in patients who are immunocompromised or have aplastic anemia (Table 1). PV B19 is a small DNA virus that in normal children
causes fifth disease, characterized by fever, malaise, and a typical bilateral cheek/ facial rash (Broliden et al. 2006). In most people, parvovirus infection is self-limited. However, parvovirus can cause complications in susceptible individuals resulting from its ability to infect erythroid progenitor cells. Patients who have undergone allogeneic hematopoietic stem cell transplants or who have sickle cell anemia can have an acute aplastic crisis as a result of parvovirus infection (Broliden et al. 2006; Eid et al. 2006). Fetuses carried by pregnant women infected with the virus can develop severe anemia, complicated by an infectious myocarditis, that can induce hydrops fetalis and fetal loss (Ergaz and Ornoy 2006). For these clinical situations, IVIG is often used (Moudgil et al. 1997; Geetha et al. 2000; Broliden et al. 2006; Eid et al. 2006). Human antibodies have been cloned that bind the major or minor capsid proteins and can neutralize parvovirus in vitro (Arakelov et al. 1993; Gigler et al. 1999). These may be candidates for cloned parvovirus antibody therapeutics.

Hepatitis A is a picornavirus, containing a positive-strand RNA genome, which causes an acute, self-limited hepatitis (Fiore et al. 2006). Prior to the creation of the recombinant hepatitis A vaccine, IVIG was routinely given for hepatitis A prophylaxis, although it was not FDA-approved for this purpose (CDC 1985; Fiore et al. 2006; Table 1). IVIG is still indicated for suspected, nonimmune contacts and for people who are intolerant of the vaccine. Native antibodies have been cloned that are specific for the capsid protein (Cerino et al. 1993) or the core antigen (Siemoneit et al. 1994), and one antibody has been cloned that is capable of neutralizing hepatitis A in vitro (Lewis et al. 1993).

The potential utility of IVIG for treatment of viruses other than PV B19 and hepatitis A is broad and reflects the collective antibody immunome of the population

| Virus                  | Globulins | Patients                              | Purpose                              |
|------------------------|-----------|---------------------------------------|--------------------------------------|
| Parvovirus B19         | IVIG      | HSCT patients                         | Treatment                            |
|                        |           | Sickled cell disease patients          | Treatment                            |
| Hepatitis A            | IVIG      | Anyone at risk                         | Prophylaxis                          |
| Hepatitis B            | Hyper-IG  | Possibly exposed to HBV                | PEP                                  |
|                        |           | Neonates                              | Inhibit vertical transmission        |
|                        |           | HBV-infected liver transplant         | Prophylaxis                          |
| CMV                    | Hyper-IG  | Solid organ transplant                 | Treatment                            |
| VZV                    | Hyper-IG  | Immunocompromised                      | Treatment of severe cases            |
|                        |           | Neutones                              | Inhibit vertical transmission        |
| VV                     | Hyper-IG  | Immunocompromised                      | Treatment                            |
| Rabies                 | Hyper-IG  | Anyone at risk                         | PEP                                  |
| RSV                    | Hyper-IG  | Premature infants/BPD                  | Prophylaxis                          |
|                        |           | HSCT patients                         | Treatment                            |

BPD, bronchopulmonary dysplasia; CMV, cytomegalovirus; HBV, hepatitis B virus; HSCT, patients who have undergone allogeneic hematopoietic stem cell transplantation; PEP, post-exposure prophylaxis; VV, vaccinia virus; VZV, varicella zoster virus
from which it is derived. A study of five different IVIG preparations revealed antiviral antibodies specific for types 1, 2, 6, and 7 herpesviruses (HSV), varicella zoster (VZV), EBV, measles, mumps, rubella, and parvovirus B19 (Krause et al. 2002). Differences in the IVIGs were also noted, in that two had high levels of antibodies specific for adenovirus and two had high levels of St. Louis encephalitis virus antibodies. A panel of eight IVIG preparations was recently examined for the presence of vaccinia virus (VV) neutralizing ability (Goldsmith et al. 2004). All were found to contain significant in vitro and in vivo VV neutralizing activity, at 3%–9% of the measured titer of standard VV hyperimmune globulins (VIG), even though widespread VV vaccination has not been practiced for nearly the past 30 years. IVIG may also have clinical activity against West Nile virus (WNV). A WNV patient in Israel recovered from the infection after treatment with IVIG. It is notable that WNV is endemic in Israel and the Israeli IVIG had a high titer of WNV antibodies. In contrast, IVIG from the United States was not found to contain WNV antibodies. IVIG has also been considered to be of potential benefit for cytomegalovirus (CMV) infection in renal and bone marrow transplants (Sechet et al. 2002; Sokos et al. 2002).

3 Hyperimmune Globulins and Native Human Antibodies for Viral Diseases

The complications of some viral infections are preferably treated with hyperimmune globulins, which are polyvalent IVIGs obtained from subjects with high-titer antibody responses to specific antigens (Table 1). Some of the viruses treated with this category of therapeutics are hepatitis B (HBV), CMV, VZV, VV, rabies, and respiratory syncytial virus (RSV). The first three of these viruses share the capability of reactivation in patients who become immunocompromised. In these settings, hyperimmune globulins are used to ameliorate the immunodeficiency and bring the reactivated viruses under control. VV causes an acute infection that can have severe manifestations in immunocompromised hosts and can be mitigated by VV-specific hyperimmune globulins. Rabies induces an acute infection that is invariably fatal, unless treated, even in immunocompetent individuals. Rabies immune globulins (RIG) provide initial control of the virus while a concomitantly administered vaccine induces permanent immunity. RSV can cause fatal bronchiolitis in premature infants and recipients of allogeneic hematopoietic stem cell transplants. In these patient populations, RSV immunoglobulins (RSV-IG) are effective for RSV prophylaxis and treatment. The different roles for hyperimmune globulins are empirically defined and reflect the unique clinical features of each virus and the infected hosts. For most of these viruses, native human antibodies have been cloned that may possess some of the functions provided by the hyperimmune globulins. Future optimized hyperimmune globulins would consist of these or similar antibodies in completely defined monoclonal or oligoclonal antiviral therapies.
3.1 Hepatitis B Virus

HBV is a partially double-stranded DNA virus that is transmitted by direct contact with infected bodily fluids (Hollinger and Liang 2001). In normal individuals, hepatitis B will generally induce a self-limited hepatitis, but it has the capacity to establish a chronic active state that can eventually lead to cirrhosis or hepatocellular carcinoma. In the United States, hepatitis B immune globulin (HBIG) is prepared from a small number of donors hyperimmunized with the HBsAg vaccine (Terrault and Vyas 2003). The main three categories of use for HBIG are (1) post-exposure prophylaxis for nonimmune contacts, (2) inhibition of vertical transmission of the virus at birth, and (3) prevention of relapse in HBV-positive patients following orthotopic liver transplantation. Following a suspected infected needle-stick or fluid exposure, HBIG is recommended to be administered in combination with the HBsAg vaccine (CDC 1984). Maternal-fetal transmission can be inhibited by administration of HBIG and the HBsAg vaccination immediately after birth to infants of mothers positive for circulating HBe antigen and HBV DNA (Lo et al. 1985; Ip et al. 1989; Kabir et al. 2006). Further improvements in outcomes may also be achieved by passive immunization of HBe-positive mothers with HBIG prior to delivery (Xu et al. 2006; Xiao et al. 2007). The successful use of orthotopic liver transplantation to treat end-stage liver disease caused by HBV depends on the prevention of reactivation of the virus in the immunocompromised, post-transplant patient (Gish and McCashland 2006). HBIG can collaborate with nucleoside antiviral agents to limit reactivation in these patients, but there remains a risk of reactivation of disease after the discontinuation of prophylactic therapy. In this setting, the cost of long-term HBIG administration may potentially be reduced through the use of low-dose combination therapy regimens (Di Paolo et al. 2004; Ferretti et al. 2004).

Many native human IgG antibodies specific for HBV have been cloned using hybridoma and EBV-immortalization methods (Stricker et al. 1985; Colucci et al. 1986; Desgranges et al. 1987; Ichimori et al. 1987; Tiebout et al. 1987; Andris et al. 1992; Ehrlich et al. 1992; Sa’adu et al. 1992; Heijtink et al. 1995). Animal data are difficult to obtain with HBV infection, but a combination of two human antibodies administered to a chimpanzee chronically infected with HBV was able to transiently (<7 days) reduce the levels of circulating virus (Heijtink et al. 1999). An important concern regarding the efficacy of cloned antibodies for HBV is the apparent ability of the virus to escape neutralization by polyclonal HBIG. This phenomenon has been observed in liver transplant patients who had recurrent HBV infection after liver transplantation despite HBIG therapy. In three studies, the existence of mutations in antigenic regions of HBsAg correlated with resistant or recurrent HBV infection (Carman et al. 1996; Ghany et al. 1998; Terrault et al. 1998). Furthermore, the length of time of therapy correlated with the likelihood of finding mutated HBV strains (Ghany et al. 1998; Terrault et al. 1998). The potential failure of polyclonal antibodies may suggest that the virus would be particularly adept at escaping the effects of a monoclonal or oligoclonal antibody therapeutic. A pair of antibodies with significant HBV binding had considerably less affinity for
a variant HBV strain that had arisen in a patient following a year of HBIG therapy (Heijtink et al. 1995). Nonetheless, it may be possible to create an oligoclonal HBIG equivalent or superior to polyclonal HBIG by identifying two or three non-cross-resistant antibodies directed at relatively stable portions of HBsAg.

### 3.2 Cytomegalovirus

CMV is a double-stranded DNA virus that, in normal individuals, induces a febrile illness that resembles mononucleosis from EBV, with chills, fatigue, headache, and malaise (Gandhi and Khanna 2004). In immunocompromised patients, such as those who have undergone bone marrow or other organ transplantation or who have advanced human immunodeficiency virus (HIV) disease, CMV can cause considerable morbidity and mortality. CMV may be reactivated in a previously infected person who becomes immunosuppressed. Alternatively, a de novo CMV infection may be transmitted to a CMV-negative recipient of an organ from a CMV-positive donor. Many organs can be affected by CMV infection, including the retina, lung, liver, esophagus, or colon. CMV can also cause complications to a fetus infected in utero, including hearing loss, visual loss, and neurological complications (Fowler et al. 1992). CMV hyperimmune globulins (CMVIG) first demonstrated efficacy in the treatment of disease associated with kidney transplants (Snydman et al. 1987). Since then, CMVIG has been approved by the FDA for treatment of CMV reactivation in patients with transplants of the kidney, heart, lung, liver, and pancreas (Sawyer 2000). Evidence does not clearly support the use of IVIG or CMVIG in allogeneic bone marrow transplant patients (Zikos et al. 1998; Sokos et al. 2002). The utility of CMVIG in organ transplant settings has been lessened by the availability of potent small molecule anti-CMV drugs, such as ganciclovir, valganciclovir, foscarnet, and cidofovir, even though these drugs have significant toxicities (Biron 2006). It is possible that CMVIG may synergize with small molecule anti-CMV drugs in some clinical situations (Kocher et al. 2003; Varga et al. 2005; Ruttmann et al. 2006).

Many native human monoclonal antibodies specific for CMV have been described (Emanuel et al. 1984; Redmond et al. 1986; Foung et al. 1989; Bron et al. 1990; Kitamura et al. 1990; Drobyski et al. 1991; Gustafsson et al. 1991; Ohizumi et al. 1992; Ohlin et al. 1993; Rioux et al. 1994). Some of these were found to be capable of neutralizing CMV in vitro (Redmond et al. 1986; Foung et al. 1989; Ohizumi et al. 1992; Ohlin et al. 1993). The native human CMV antibody, MSL-109, has been tested for clinical efficacy (Drobyski et al. 1991). In a randomized controlled trial of allogeneic hematopoietic stem cell transplant patients, no benefit from the antibody was seen in terms of the time to development of CMV viremia or pp65 antigenemia (Boeckh et al. 2001). Studies of the MSL-109 antibody in AIDS patients with newly diagnosed or recurrent CMV retinitis did not show a reduction in the progression of CMV disease (CDC 1997a; Borucki et al. 2004). The explanation for these disappointing results is unclear.
The MSL-109 antibody is specific for the H glycoprotein (gp86). It is possible that an antibody specific for the B glycoprotein complex (gp58/116), a major target of CMV neutralizing antibodies, may be useful alone or in combination with an anti-H antibody (Ohlin et al. 1993). Nonetheless, the most likely explanation may be that T cell function is essential for CMV control in vivo and that neutralizing antibodies are minimally active in the absence of robust T cell activity (Boeckh et al. 2003).

### 3.3 Varicella Zoster Virus

VZV is a highly transmissible, double-stranded DNA poxvirus that induces a febrile illness (chickenpox), which is characterized in children by fever, malaise, and a pruritic, vesicular rash (CDC 1996). VZV can also reactivate in adulthood as a series of painful vesicular lesions in the distribution of a cutaneous dermatome. Infection of pregnant women during the first and second trimesters may induce the congenital varicella syndrome, which can result in significant fetal deformities, and VZV infection transmitted to newborns can be fatal (Tan and Koren 2006). Accordingly, VZV immunoglobulins (VZIG) are indicated for immunocompromised patients, pregnant women, and neonates at risk for VZV infection (CDC 2006; Tan and Koren 2006). Native human antibodies capable of neutralizing VZV in vitro have been cloned (Foung et al. 1985; Sugano et al. 1987, 1991).

### 3.4 Vaccinia Virus

One of the established uses of human hyperimmune globulins is the treatment of complications of vaccinia virus (Lane et al. 1969; Henderson et al. 1999). Vaccinia virus is a poxvirus that has been adapted for use as a human vaccine for the prevention of smallpox. Although generally safe for immunocompetent persons, disseminated and occasionally fatal infections can occur among patients with underlying immunodeficiencies, such as those with HIV infection, eczema, or atopic dermatitis (Henderson et al. 1999). Generalized vaccinia is a syndrome in which VV proliferation is systemically spread through the bloodstream (Redfield et al. 1987). Progressive VV infection is characterized by unrestrained proliferation of virus in the skin. Eczema vaccinatum is the excessive proliferation of VV in the skin lesions of eczema patients. For these conditions, VIG is indicated and can often lead to a complete resolution of symptoms (Henderson et al. 1999). VIG is also useful in immunocompetent individuals who have a complicated infection, such as may result from accidental infection of the periorbital region (Lewis et al. 2006).

Creation of cloned neutralizing antibody therapeutics for VV may be challenged by its complex life cycle. The VV virion exists in two forms that differ in their ability to be neutralized by antibodies, the intracellular mature virion (IMV) and the extracellular enveloped virion (EEV), with the IMV more susceptible to neutralization.
than the EEV (Law and Smith 2001; Smith et al. 2002). Optimal protection against lethal VV in murine and rhesus macaque models by a DNA vaccine required a combination of four genes directed at both the IMV and EEV (Hooper et al. 2003). A cloned native murine antibody specific for the A27L antigen (a neutralization target of the IMV) was able to protect mice prophylactically and therapeutically from a lethal VV challenge (Ramirez et al. 2002). However, no comparable native or nonnative human antibodies have been described. It will be important, however, to determine how many cloned human antibodies will be required to improve the symptoms of VV infection in immunocompromised patients.

3.5 Rabies Virus

Rabies is a virus with a single-stranded RNA genome that causes an acute and universally fatal encephalitis. The efficacy of RIG for the post-exposure prophylaxis of rabies has been reviewed elsewhere in this volume (see the chapter by T. Nagarajan et al.). Briefly, human rabies immunoglobulins (HRIG) are used in combination with rabies vaccination for a known or suspected rabies exposure, administered intravenously as well as directly into the suspected exposure site (see the chapter by T. Nagarajan et al., this volume). Native human antibodies have been cloned that are capable of neutralizing the virus in vitro and in vivo; most of these are reactive with the rabies glycoprotein (Dietzschold et al. 1990; Gebauer and Lindl 1990; Lafon et al. 1990; Ueki et al. 1990; Enssle et al. 1991; Dorfman et al. 1994; T. Nagarajan et al., this volume). A combination of two human antibodies that bind noncross-resistant epitopes on the glycoprotein has undergone preclinical in vivo testing. One of the antibodies was a native antibody and the other was cloned using the phage display method (Champion et al. 2000; Bakker et al. 2005). The antibody combination demonstrated efficacy comparable to HRIG and did not interfere with the potency of a simultaneously administered rabies vaccine (de Kruif et al. 2006).

3.6 Respiratory Syncytial Virus

RSV is a single-stranded, negative-strand virus that usually causes an upper respiratory infection (Welliver 2003). In some patient populations, RSV infection can develop into a bronchiolitis, an inflammation of the bronchioles, the smallest air passages of the lung. It is an important cause of mortality in young children and the elderly, and no vaccine for the disease currently exists (Shay et al. 2001; Thompson et al. 2003; Falsey et al. 2005). RSV exists in two main subtypes, A and B, but infection with one subtype does not even provide lifelong protection from reinfection by the same subtype (Welliver 2003). Premature infants and those affected by bronchopulmonary dysplasia (BPD) are at increased risk for hospitalization and death from RSV bronchiolitis (Aujard and Fauroux 2002). The prevalence of RSV infection in this population can be reduced by prophylactic
treatment with RSV-IG (CDC 1997b). In contrast, RSV-IG did not show any efficacy in the treatment of infants already admitted to the hospital with the disease (Rodriguez et al. 1997). RSV may also cause a fatal bronchiolitis in patients undergoing allogeneic stem cell transplantation, and off-label administration of RSV-IG with the antiviral drug ribavirin may reduce mortality (DeVincenzo et al. 2000; Ghosh et al. 2000; Small et al. 2002).

No native human antibodies that neutralize RSV have been cloned. However, a humanized murine monoclonal antibody, palivizumab, is a potent substitute for RSV and the first demonstration of the utility of a monoclonal antibody as an antiviral therapeutic (Young 2002; see the chapter by H. Wu et al., this volume). Palivizumab binds an epitope on the F glycoprotein, a viral surface protein that is a major target for neutralizing antibodies and is highly conserved between type A and B viruses. In a series of high-risk infants with prematurity and/or BPD, a course of monthly prophylactic doses of palivizumab reduced the overall rate of serious infections and hospitalizations by 55% (CDC 1998). A role for palivizumab in the treatment of RSV infection in the elderly or in allogeneic hematopoietic stem cell patients has not yet been established.

### 3.7 Cloning Antibody Therapeutics for Viral Disease

The potency of IVIG, hyperimmune IGs, and the monoclonal antibody palivizumab demonstrate in principle that human antibody therapeutics are likely to be effective for the treatment of viral diseases. A vast, unmet medical need exists for treatments for the majority of viral diseases that occur worldwide. The development of antiviral antibody therapeutics will be challenged by the diversity of virus types, patient populations and the roles antibodies play in the neutralization of specific viruses, the ability of viruses to mutate antigenic domains, and an incomplete understanding of the specific features that endow an antibody with neutralizing ability. To counter these uncertainties it will be important to explore as diverse an antibody repertoire as possible, which can best be achieved by using a variety of different, complementary methods for human antibody cloning. The efficacy of IVIG and hyperimmune IGs suggests that an ideal starting point to clone a human antibody capable of potently neutralizing a viral pathogen may be with B cells from subjects who have developed a definitive antiviral body response, either by infection or vaccination. Native antibody libraries created from these affinity-matured B cells would be expected to contain individual antibodies that possess virus-neutralizing abilities and would be suitable for use as monoclonal or oligoclonal antibody therapeutics. The successes of native human antibody cloning methods in obtaining native human antiviral antibodies, and the potency of these antibodies, establish a rationale for further exploration of these methods. It is evident that the effectiveness of this approach will depend on the ability to create libraries that come as close as possible to comprehensively incorporating the entire diversity of the human antibody response to viral pathogens.
4 Features of Different Cloned Human Antibody Repertoires

The prevalent methods of cloning human antibodies from immune human repertoires differ in bias and in the degree to which they sample antibodies in their native configurations (e.g., with the original heavy chain:light chain pairing). B cell immortalization methods, which use hybridoma generation or EBV infection to enable primary human B cells to proliferate in vitro, theoretically take an unbiased sample of the repertoire of B cells and express each antibody with native heavy chain:light chain pairings. In addition to the antibodies described in the preceding section, these methods have been used to clone native human antibodies specific for measles, HIV, severe acute respiratory syndrome (SARS), EBV and hepatitis C. These methods have historically been challenged by poor antibody yields and unstable antibody secretion. Nonetheless, they have been the focus of ongoing optimization efforts that should improve their ability to comprehensively access the native human antibody immunome.

Recombinant DNA methods offer a well-established method for cloning human antibody repertoires. In these methods, heavy chain and light chain variable domains are amplified from B cell populations using RT-PCR, fused, and expressed as single-chain antigen-binding domains (scFv) on the surface of filamentous phages (Barbas 1993; Winter et al. 1994). Screening for specific antibodies is performed by panning for virus that binds to a plate or other solid support coated with antigen (Bradbury and Marks 2004). A related technology is yeast display, in which the scFv molecules are expressed on the surface of Saccharomyces cerevisiae (Boder and Wittrup 1997). Yeast display allows greater diversification of expressed antibody sequences by mutagenesis and has the advantage that yeast cells expressing human antibody can be directly screened by flow cytometry with fluorescent antigen, enabling a rapid assessment of binding kinetics. Libraries of scFv antibodies have also been efficiently expressed on the surface of Escherichia coli (Daugherty et al. 1999).

It is clear that recombinant DNA libraries obtained from immune individuals differ from antibodies obtained from nonimmune individuals (Amersdorfer et al. 2002). However, the process of creating these libraries can introduce bias at different steps in the process that may hinder their ability to capture the entire native antibody repertoire. The first step is an RT-PCR amplification with consensus DNA primers, which may not equally amplify each immunoglobulin gene sequence. The second is at the level of expression in phage, because E. coli does not express all eukaryotic peptides with the same efficiency, and human variable domain gene sequences can differ significantly from one another in their length and amino acid composition (Pavoni et al. 2006). A combination of these effects could potentially reduce the prevalence of specific antibodies in the antibody libraries or eliminate them entirely.

Evidence that this occurs comes from DNA sequence analysis of complementarity-determining (CDR) regions of heavy chain variable domains (V_H) cloned by phage display. The third CDR region (CDR3) of the V_H is the most important contributor to the antigen-binding specificity of an antibody (Xu and Davis 2000). CDR3 regions incorporated into phage display libraries tend to be short (less than
15 amino acids), whereas CDR3 regions in native human antibodies vary widely in length, with many over 20 amino acids in length (Griffiths et al. 1994; Brezinschek et al. 1995; Tian et al. 2007). Shorter CDR3 regions correlate overall with greater levels of somatic hypermutation, but longer CDR3 regions may be better capable of viral neutralization (Saphire et al. 2001; Hangartner et al. 2006; Tian et al. 2007). It is possible that shorter CDR3 regions are selected against at the level of PCR amplification or expression in *E. coli*.

Two studies have directly examined the types of immune libraries that arise from phage display and hybridoma methods. In one comparative study, antibodies cloned from mice immunized with human interleukin-5 protein using phage display and hybridoma methods were compared (Ames et al. 1995). Each method produced a structurally distinct group of antibodies, and only the antibodies cloned by the hybridoma method were able to block binding of the cytokine with its receptor. Ohlin and Borrebaeck (1996) analyzed a dataset of cloned antibody sequences specific for infectious disease antigens, the majority of which were viral, and were cloned by either the phage display or hybridoma method (Ohlin and Borrebaeck 1996). They noted substantial differences in the heavy chain and light chain gene family utilization between antibodies derived from the two different sources. They also noted a dramatic limitation of the diversity of the light chain gene repertoire. This observation may have been due to the phenomenon of light chain promiscuity, i.e., the ability of heavy chains to productively associate with a variety of light chains (Kang et al. 1991).

The ability of a phage library to recreate native heavy chain:light chain combinations was recently assessed by comparing a phage display antibody library that maintained native pairings with one made from the same cDNA that did not (Meijer et al. 2006). In the random library, the assortment of heavy chain and light chain sequences had apparently lost a majority of the original heavy chain:light chain pairings. Consistent with the principle of light chain promiscuity, the diversity of the random library was less than the nonrandom library due to an over-representation of VH chains capable of associating with many different light chain sequences. The functional importance of the antibody repertoire shift in the random library was revealed by the overall lower affinity of antibodies specific for tetanus toxoid (TT) antibodies cloned from the two libraries.

Taken together, these experiments illustrate the concept that intrinsic biases in phage display libraries may prevent some important native antibody structures from being incorporated into them. B cell immortalization methods of human antibody cloning are therefore complementary to recombinant DNA methods and thus merit further study and optimization.

### 5 Hybridoma Methods to Clone Native Human Antibodies

As a starting point in native human antibody cloning methods, the source of virus-immune B cells is an immune individual who has generated an antibody response that is effective in collaborating with the human immune system to cure the viral
infection. Thus, there can be a presumption that antibodies with the requisite biological functions exist within the volunteer B cell donor. Donors can be subjects who have either (1) received vaccines specific for the virus, (2) survived an infection by the relevant virus, or (3) have succumbed to the viral infection but have made spleen, lymph nodes, or peripheral blood mononuclear cells (PBMCs) available post mortem. The use of B cells from a variety of genetically unrelated individuals can increase the diversity of the native antibody libraries to be screened.

There are many approaches to cloning human antibodies in their native configurations. For the most part, these involve methods of converting primary human B cells into a form that is viable in vitro through EBV immortalization, hybridoma formation, or a combination of these protocols. In EBV immortalization, purified B cells are infected with EBV-containing supernatant from the B95-8 marmoset cell line (Brown and Miller 1982). These methods are effective, yet they can be compromised by the low levels of antibody that are typically expressed by EBV-transformed cells (lymphoblastoid cells, LCLs) (Stein and Sigal 1983). In hybridoma methods, primary human B cells are fused to an immortal fusion partner cell line, which is adapted to in vitro culture and capable of producing high levels of antibody from immunoglobulin genes provided by the primary B cell. The primary impediments to hybridoma approaches have been low hybrid cell yields and the loss of antibody expression, which correlates with the loss of human chromosomes from the hybrid cells. Combination approaches have been taken that can overcome some of these defects by immortalizing and expanding the antigen-specific B cell population first with EBV infection, and then fusing the immortalized cells to a murine or murine/human fusion partner cell line.

5.1 Improvements in Fusion Partner Cell Lines

Most of the technology development in this area has attempted to address the problem of hybridoma instability by improving the fusion partner cell line. It had originally been considered that human cell lines would be optimal as fusion partners for primary human B cells because hybrid cells formed between murine cells and human cells were known to segregate human chromosomes (Ephrussi and Weiss 1969). The first reported human antibody cloning by a hybridoma method was an IgM antibody specific for measles virus (Croce et al. 1980). For this purpose, Croce et al. used a human myeloma cell line as a fusion partner cell and PBMCs from a patient with subacute sclerosing panencephalitis, the clinical syndrome resulting from measles virus infection of the central nervous system. Shortly thereafter appeared the first report of use of an EBV-immortalized B cell line as a fusion partner to clone antibodies specific for TT (Chiorazzi et al. 1982). An EBV-immortalized human B cell expressing an antibody to CMV was fused to a human myeloma cell line to give a hybrid with improved antibody expression (Emanuel et al. 1984). Enthusiasm for human cell lines was tempered, however, due to problems with the limited number of immortalized myeloma and other B cell lines that were available (Kozbor et al. 1986). Most of the cell
lines had low fusion rates and produced slow-growing hybridomas, and many already expressed human antibody genes. Chromosomal instability was also observed to be a considerable problem (Olsson et al. 1983).

Experiments using murine myeloma cell lines as fusion partners for human B cells demonstrated a poor efficiency that likely resulted from the strong tendency of murine/human hybrid cells to rapidly segregate human chromosomes (Ephrussi and Weiss 1969; Schlom et al. 1980; Kozbor et al. 1982; Koropatnick et al. 1988). To compensate for the defects intrinsic to human and murine partner cell lines, a variety of heteromyeloma (murine and human) cell lines have been created. The general approach taken was to fuse murine myeloma cell lines with human cells, either normal PBMCs (Foung et al. 1984; Ichimori et al. 1985; Grunow et al. 1988) or malignant cells (Carroll et al. 1986; Posner et al. 1987; Faller et al. 1990; Shirahata et al. 1998).

Where examined, these fusions have generally resulted in hybrid cells with chimeric murine/human genomes that appear to be improved fusion partners for creating hybridoma cells that stably secrete human antibodies. For instance, the CB-F7 and the SPAM-8 heteromyelomas contained no distinct human chromosomes, but did contain human DNA detectable by hybridization analysis, probably in the form of murine/human chimeric chromosomes (Grunow et al. 1988; Gustafsson et al. 1991). The heteromyeloma cell lines K6H6/B5, HAB-1, HM-5, and SPC-H20 all possessed independent, metacentric chromosomes, consistent with a human origin (Foung et al. 1984; Ichimori et al. 1985; Carroll et al. 1986; Faller et al. 1990). When directly compared to the parental murine myeloma cell lines, the heterohybridoma fusion partner cell lines tended to have an improved ability to give rise to hybrid cells that stably expressed human antibodies (Foung et al. 1984; Carroll et al. 1986; Grunow et al. 1988; Faller et al. 1990). As many of the hybrid cells derived from these fusion partner cells contained substantial numbers of human chromosomes, it is likely the heteromyeloma cell lines were better able to produce hybrid cells with a reduced tendency to segregate human chromosomes (Foung et al. 1984; Carroll et al. 1986; Grunow et al. 1988; Faller et al. 1990). Using heteromyeloma fusion partner cell lines, a wide variety of native human antibodies have been cloned that were specific for important viral pathogens. These included the human T cell lymphotropic virus (HTLV-1), CMV, HBV, hepatitis C virus (HCV), HIV, and VZV (Foung et al. 1984; Carroll et al. 1986; Grunow et al. 1988; Bron et al. 1990; Faller et al. 1990; Gustafsson et al. 1991; Hadlock et al. 1997, 2000).

5.2 Methods of Preparing Human B Cells for Fusion

Along with the improvements in the fusion partner cell lines, the parameters affecting the rate of productive hybrid cell formation have been systematically analyzed. The best sources of primary human B cells are the splenic mononuclear cells, tonsils, or peripheral blood mononuclear cells from infants (Olsson et al. 1983; Grunow et al. 1988; Jessup et al. 2000; Karpas et al. 2001). The time of
harvest of B cells following a vaccination is also important, with the best outcomes with TT antibodies seen with cells obtained 5–7 days following the vaccination, which corresponds to the period of time when the maximum quantity of TT-specific memory B cells is circulating in the blood (Butler et al. 1983; Lanzavecchia et al. 2006). Treatment of the primary B cells with a proliferative stimulus prior to fusion is also essential, either with pokeweed mitogen (PWM) or EBV (Butler et al. 1983; Larrick et al. 1983; Olsson et al. 1983; Cole et al. 1984; Emanuel et al. 1984). PWM is superior to phytohemagglutinin and is optimally used for 5–7 days (Olsson et al. 1983; Arinbjarnarson and Valdimarsson 2002). Costimulation of mitogen-treated cells with antigen can increase the yield of antigen-specific antibodies (Butler et al. 1983; Sugano et al. 1987). During the cell fusion, the ratio of B cells to immortal fusion partner cells is an important variable (Butler et al. 1983; Perkins et al. 1991).

Two groups of investigators have noted improvements in fusion efficiencies when the PBMCs are expanded prior to cell fusion using the CD40 system, an in vitro cell culture method that uses antibodies specific for CD40 and interleukin (IL)-4 to stimulate B cell proliferation and survival in vitro prior to cell fusion (Banchereau and Rousset 1991; Darveau et al. 1993; Thompson et al. 1994). Some of the benefit from expansion of the B cells in the CD40 system or by EBV-immortalization may derive from removing cytotoxic cells from the fusion that may threaten the viability of nascent heterohybridoma cells, which presumably express a variety of murine protein antigens, in the context of human MHC, that may be recognized as foreign by the human cytotoxic cell population. Consistent with this hypothesis, Borrebaeck and his colleagues demonstrated a dramatic improvement in the yields of murine/human and human/human cell fusions when they treated the input PBMCs with l-leucine methyl ester (Leu-OMe), which is toxic to lysosome-rich cytolytic cells, including natural killer (NK) cells and some T cells (Borrebaeck et al. 1987; Borrebaeck et al. 1988). A similar potential effect on cytotoxic, unfused cells was observed by Kalantarov et al. with the murine/human fusion partner cell line MFP-2S, which carried the neo drug-resistance marker. Inclusion of G418 in the cell culture medium post-fusion substantially reduced the variability of yields of antibody-secreting hybrid cells (Kalantarov et al. 2002). In principle, it may be helpful to enrich cell populations for expression of specific antibodies prior to cell fusion. In a report approximately 20 years ago, Casali et al. selected B cells expressing antibodies specific for TT prior to EBV immortalization (Casali et al. 1986). More recently, in comparison to results obtained with unselected PBMCs, fusions performed with CD19-selected B cells had increased hybridoma yields (Schmidt et al. 2001).

5.3 Electrofusion and Hybrid Cell Culture

As an alternative to traditional chemical methods of inducing cell fusion with polyethylene glycol (PEG), electrofusion can offer dramatically improved rates of cell fusion (Pratt et al. 1987; Foung et al. 1990; Perkins et al. 1991). In electrofusion,
the cells to be fused are aligned in a hypoosmolar buffer solution using an alternating current. Fusion is then induced by one or more bursts of direct current. Electrofusion has been used with a variety of fusion partner cell lines, including lymphoblastoid, heteromyeloma and murine myeloma cell lines (Pratt et al. 1987; Foung et al. 1990; Yoshinari et al. 1996). Three studies have directly compared the efficiency of electrofusion and polyethylene glycol (PEG) fusion, estimating an apparent superiority of electrofusion of 4- to 100-fold, with a maximal calculated fusion rate of approximately 1 cell per 1,000 input human B cells (Perkins et al. 1991; Krenn et al. 1995; Panova and Gustafsson 1995). To improve the viability of hybrid cells following fusion, a delay of 24 h prior to the initiation of HAT selection (hypoxanthine, aminopterin, thymidine) and the use of cell feeder layers to support hybridoma growth have also been found to be helpful (Cote et al. 1983; Perkins et al. 1991; Hoffmann et al. 1996; Shirahata et al. 1998).

6 Recent Advances in Native Human Antibody Cloning

Improvements continue to be made in the fusion partner cell lines. The Karpas 707H cell line is a near-tetraploid human myeloma cell line that has been specifically selected for improved growth rates in vitro and resistance to PEG, which is required for cell fusion but which was toxic to the original myeloma cell line (Karpas et al. 2001). Karpas 707H effectively fuses with tonsillar B cells and lymphoblastoid cells and is notable for the creation of hybridomas that secrete up to 210 µg antibody/ml culture medium. An analysis of the antibodies cloned from thymocytes fused to the Karpas 707H cell line revealed a spectrum of antibodies representing different stages in the B cell differentiation process (Vaisbourd et al. 2001).

MFP-2B is a novel heterohybridoma cell line that is actually the progeny of two cell fusions. The first was between a murine myeloma cell line and a human myeloma cell line. The second was between one of the resultant heterohybridomas and primary human lymphocytes obtained from a lymph node (Kalantarov et al. 2002). The MFP-2B has been additionally modified to express a neo resistance gene, enabling negative selection against cytotoxic cells following the cell fusion (Kalantarov et al. 2002). This cell line is notable for its fusion and cloning efficiency. A karyotype demonstrates no intact human chromosomes, but 40% of the chromosomes are partial human chromosomes or chimeric murine/human chromosomes. The MFP-2B cell line has also been used to clone antibodies specific for breast cancer antigens (Kirmann et al. 2002).

An important alternative to hybridoma methods is a recently improved EBV-immortalization method, in which human primary CD19+IgG+B cells are stimulated with a CpG oligonucleotide prior to EBV exposure (Hartmann and Krieg 2000; Traggiai et al. 2004). The polyclonal B cell proliferation increases the rate of EBV immortalization from 1%–2% to 30%–100%. In addition, the efficiency of cloning the transformed cells was improved by including CpG oligonucleotides in the culture medium and using an irradiated mononuclear cell layer. Others have
noted that lymphoblastoid cells tend to have unstable IgG expression, but the immortalized cells were found to produce 3–20 µg antibody/ml supernatant and were stable enough to enable in vitro and in vivo functional experiments (Stein and Sigal 1983; Traggiai et al. 2004). This method enabled the cloning of a panel of IgG antibodies specific for either the nucleoprotein or the spike protein of the SARS virus, some of which were able to significantly reduce proliferation of the virus in a murine disease model (Traggiai et al. 2004).

Improvements have also been made in phage display methods that may mitigate some of the factors that hinder the incorporation of native human antibody genes into typical phage display libraries. As described above, Meijer et al. employed a novel approach of in-cell, single-cell PCR with consensus oligonucleotides that produce an individual, correctly paired scFvs from each cell (Meijer et al. 2006). These scFvs were then used to create a phage display library for screening. Analysis of the paired sequences produced by this method demonstrated consistent pairing of the same heavy and light chains, indicating preservation of the native paired antibody conformations.

7 The Use of Ectopic Gene Expression to Improve Hybridoma Stability

Little is understood about the causes of the intrinsic instability of hybridomas formed with primary human B cells or of the segregation of human chromosomes by murine/human hybrid cells (Ephrussi and Weiss 1969; Cieplinski et al. 1983; Harris et al. 1990). To begin to address these questions empirically, we and others have considered that empiric modification of fusion partner cells by ectopic gene expression may provide insight into the nature of hybridoma cells while potentially improving their utility.

The first experiments along these lines were based on the observation that addition of IL-6 to the culture medium of murine/murine cell fusions could increase the proportion of hybrid cells expressing murine antibody (Bazin and Lemieux 1989). Interleukin-6 is essential for myeloma cell growth, possessing proliferative and antiapoptotic functions, in addition to the ability to directly stimulate antibody gene expression (Hirano 1998). Addition of IL-6 to hybridoma culture medium improved the cloning efficiency and antibody secretion of established hybridomas (Zhu et al. 1993). SP2/0 cells ectopically expressing high level mIL-6 (SP2/mIL-6) were found to give improved yields of hybridomas secreting both antigen-specific and nonspecific antibodies, compared with untransfected, parental SP2/0 cells (Harris et al. 1992).

A similar experiment was performed with the goal of improving the stability of murine/human cell fusions (Zhu et al. 1999). Interleukin-11 (IL-11), which shares many functions with IL-6, was ectopically expressed in a murine fusion partner cell line. Expression of IL-11 improved the yields of hybridomas following selection, and this effect was noted with both mitogen-stimulated and EBV-transformed
B cells. IL-11 expression also increased the quantity of antibody produced by hybrids derived from stable LCLs. However, no data were given on the long-term stability of the hybridomas. It is likely that they were still prone to segregation of human chromosomes and the associated loss of antibody expression. We performed similar experiments, comparing the ability of the SP2/mIL-6 and SP2/0 fusion partner cell lines to form stable hybrids with human splenic B cells. Expression of mIL-6 was not able to overcome the instability resulting from the segregation of human chromosomes (Dessain et al. 2004; K. Rybinski, S. Adekar, B. Barnoski, S. Dessain, unpublished data).

We originally considered that ectopic expression of human telomerase (hTERT) may improve fusions between human B cells and human immortal fusion partner cell lines. Human/human hybridomas are affected by poor proliferation rates and chromosome loss, both phenotypes having been associated in other cell culture systems with telomere dysfunction (Olsson et al. 1983; Counter et al. 1992; Bailey and Murnane 2006). Prior to the discovery of hTERT, experiments had shown that mortal human T cells impose a dominant senescence program when fused to immortal human cells (Pereira-Smith et al. 1990). Later, microcell fusion experiments revealed that the introduction of an intact copy of human chromosome 3 into an immortal, hTERT-expressing cell line repressed hTERT activity and caused cellular senescence (Oshimura and Barrett 1997). Together, these results suggested that human/human hybrid cells, formed between immortal fusion partner cell lines and primary human B cells, suffered from hTERT deficiency. Unfortunately, initial experiments with human fusion partner cell lines suggested that their deficiencies were multifactorial and could not be overcome solely by ectopic hTERT expression (S. Dessain, R. Goldsby, R. Weinberg, data not shown).

Because murine fusion partner cell lines are much better at forming hybrids than most human fusion partners, we performed similar experiments with the SP2/0 cell line (Shulman et al. 1978). The SP2/0 cell line is a very poor fusion partner for primary human B cells, so it served as a useful starting point to assess the affect of ectopic gene expression (Jessup et al. 2000). In murine/human hybrid cells, hTERT could potentially contribute to hybrid cell stability by a species-specific stabilization of human telomeres. In addition, hTERT has been shown to have many other functions that may be beneficial to hybrid cells, including an incompletely characterized tumor-promoting function that may be related to its antiapoptotic and growth factor-stimulatory activities (Holt et al. 1999; Stewart et al. 2002; Kanzaki et al. 2003; Smith et al. 2003). We found that most heterohybridoma cells formed between the SP2/0 cell line and primary human B cells expressed murine TERT (mTERT), but not hTERT. We introduced hTERT into SP2/0 cells, observing a modest increase in the numbers of cells expressing hTERT, but without useful, long-term maintenance of human antibody expression (S. Dessain, R. Goldsby, R. Weinberg, data not shown). In contrast, the ectopically expressed combination of hTERT and mIL-6 readily enabled the creation of stable hybrid cells secreting human antibodies. Notably, the hybridomas that resulted from these fusions contained considerable numbers of intact human chromosomes, even after 3 months of continuous culture in vitro (Dessain et al. 2004). An example of this is shown in Fig. 1, the human
some of the apparent cooperative benefit of the hTERT and mIL-6 genes may result from a mechanism whereby mIL-6 expression may promote the maintenance of human chromosomes by nascent hybridoma cells. Hybrid cells created by SP2/0 cells and human primary B cells do not proliferate in culture because the human chromosome 21 represses mIL-6 expression by the hybrid cells (Ebeling et al. 1998). Therefore, proliferation of the hybrid cells in vivo may only be possible after this chromosome is lost, indirectly selecting for cells that rapidly segregate human chromosomes. The specific mechanisms whereby mIL-6 and hTERT collaborate in chromosome maintenance are under investigation.

8 High-Throughput Screening Technologies

Following their establishment through cell fusion and drug selection, hybridomas need to be screened for specific antibody expression. In an optimal approach to thoroughly explore the native antibody immunome, each hybridoma would be

![Human chromosomes in a human/murine heterohybridoma](image)
assayed individually for the binding specific of its particular antibody. Because of practical considerations, hybridomas are generally assayed in pools of dozens or more clones, but advanced screening technologies may significantly increase the yields of specific antiviral antibodies that could be obtained. New antibody screening methods differ in how they achieve the core objective of associating individual cells with the antibodies they produce. In the selected lymphocyte antibody method (SLAM), primary B cells are cultured in the presence of complement and sheep red blood cells (SRBC) conjugated to the antigen of interest (Babcock et al. 1996). B cells expressing antibodies specific for the SRBC-conjugated antigen can be identified because their secreted antibodies cause localized hemolytic reactions. Although it was originally conceived that this method would be used with primary B cells from which immunoglobulin genes would be directly cloned by RT-PCR, this method may be useful for screening hybridomas or EBV-transformed cells.

Three methods combine the isolation of individual hybridoma cells with fluorescent assays for antigen binding. The first distributes individual hybridomas into tiny wells (0.1–1 nl volume) created on glass slides using a microengraving technique (Love et al. 2006). The secreted antibodies are captured for analysis by sandwiching the arrayed hybridoma supernatants with a capture slide that is coated with secondary antibody or antigen. The bound complexes are then detected with fluorescently labeled antigens or secondary antibodies, respectively. Multiple capture slides can be used with a single hybridoma microarray, enabling cells to be screened for a variety of antigen-binding specificities. An alternate method immobilizes hybridomas on a filter through which secreted antibodies diffuse and then bind to a plate coated with a secondary antibody (www.trellisbio.com; Potera 2005). The plate is then probed with a panel of fluorescent probes that can be used in a combinatorial fashion to allow simultaneous screening for many different antigens. Computerized microscopy is used to analyze the binding reactions. Hybridomas can also be enveloped in an agarose matrix that captures the antibodies secreted by the hybridomas. For this purpose, secondary antibodies are attached to the agarose through a biotin-avidin bridge (Gray et al. 1995). The secreted antibodies are thus stably associated with the cells that produce them. The porous agarose matrix enables the hybridomas to be screened for binding to fluorescently labeled antigens. The matrix also offers structural stabilization for the hybridomas so that they can be analyzed and sorted by FACS.

In one of our laboratories (J.B.) we have begun experiments with the FMAT 8200 Cellular Detection System. This system uses antigen-coated beads, which are mixed with hybridoma supernatants and fluorescently labeled secondary antibodies in 96-well or 386-well formats. The secondary antibodies detect specific antibody bound to the beads, thereby concentrating the fluorescence into punctate signals that are detected by a mechanized plate reader. The advantage of this method is that it enables high-throughput screening of hybridoma supernatants, but it does not provide a means of isolating single cells prior to screening. Finally, the marriage of such cell screening technologies with automated cell manipulators (ClonePix, www.genetix.com) will accelerate the process of mining the native human antibody immunome to obtain antibodies for use in the treatment of viral diseases.
9 Summary and Future Prospects

The pressing demand for antibodies for use as antiviral therapeutics mandates a broad-based effort that utilizes all of the available antibody cloning technologies in parallel. Cloning methods that directly immortalize B cells through hybridoma creation or EBV infection can complement recombinant DNA and transgenic mouse methods of antibody cloning because they have an unbiased access to antibody repertoires in their native configurations. In addition, these methods simplify the exploration of the antibody repertoires of genetically diverse individuals. Over the past 27 years, successive technical advances have improved the methods for cloning native human antibodies such that they now may be able to contribute meaningfully to ongoing efforts with phage display and transgenic mouse methods. The simplicity of these methods should facilitate their application by laboratories with a diversity of research interests, as well as provide a rationale for creating core facilities that provide high-throughput screening services to academic and other researchers.

Acknowledgements We are grateful to Mary Guttieri and Jay Hooper of USAMRIID, Frederick, MD, for reagents used to clone the VV A27L hybridoma described in Fig. 1. We also thank Maria L. Skorski and Barry L. Barnoski for the karyotype shown in Fig. 1. For guidance and discussion we thank Hilary Koprowski, Richard Goldsby, Lance Simpson, Gordon Freeman, T. Nagarajan, Ike Eisenlohr, and Tara Robinson. This work was supported by NIH grants R01-HL081503 and R01-AI065967 (S.K.D.) and the CBRN Research Technology Initiative (J.D.B.).

References

Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD (2002) Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 20:1640–1648

Ames RS, Tornetta MA, McMillan LJ, Kaiser KF, Holmes SD, Appelbaum E, Cusimano DM, Theisen TW, Gross MS, Jones CS, et al (1995) Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display library. J Immunol 154:6355–6364

Andris JS, Ehrlich PH, Ostberg L, Capra JD (1992) Probing the human antibody repertoire to exogenous antigens. Characterization of the H and L chain V region gene segments from anti-hepatitis B virus antibodies. J Immunol 149:4053–4059

Arakelov S, Gorny MK, Williams C, Riggin CH, Brady F, Collett MS, Zolla-Pazner S (1993) Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. J Infect Dis 168:580–585

Arinbjarnarson S, Valdimarsson H (2002) Generation of heterohybridomas secreting human immunoglobulins; pokeweed mitogen prestimulation is highly effective but phytohemagglutinin drives most B cells into apoptosis. J Immunol Methods 259:139–148

Aujard Y, Fauroux B (2002) Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 96 [Suppl B]:S9–S14

Babcock JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW (1996) A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A 93:7843–7848
Exploring the Native Human Antibody Repertoire

Bailey SM, Murmane JP (2006) Telomeres, chromosome instability and cancer. Nucleic Acids Res 34:2408–2417

Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Nieszgoda M, Hanlon CA, Thijssen S, Backus HH, de Kruijf DJ, Dietzschold B, Rupprecht CE. Goudsmit J (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79:9062–9068

Banchereau J, Rousset F (1991) Growing human B lymphocytes in the CD40 system. Nature 353:678–679

Barbas CF 3rd (1993) Recent advances in phage display. Curr Opin Biotechnol 4:526–530

Bazin R, Lemieux R (1989) Increased proportion of B cell hybridomas secreting monoclonal antibodies of desired specificity in cultures containing macrophage-derived hybridoma growth factor (IL-6). J Immunol Methods 116:245–249

Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71:154–163

Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553–557

Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:343–351

Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414

Borrebaeck CA, Danielsson L, Moller SA (1987) Human monoclonal antibodies produced from L-leucine methyl ester-treated and in vitro immunized peripheral blood lymphocytes. Biochem Biophys Res Commun 148:941–946

Borrebaeck CA, Danielsson L, Moller SA (1995) A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with cytomegalovirus retinitis. Antiviral Res 64:103–111

Bradbury AR, Marks JD (2004) Antibodies from phage antibody libraries. J Immunol Methods 290:29–49

Brezinschek HP, Brezinschek RI, Lipsky PE (1995) Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol 155:190–202

Broliden K, Tolfvenstam T, Norbeck O (2006) Clinical aspects of parvovirus B19 infection. J Intern Med 260:285–304

Bron D, Delforge A, Lagneaux L, De Martynoff G, Bosmans E, Van der Auwera P, Snoeck R, Burny A, Strycmans P (1990) Production of human monoclonal IgG antibodies reacting with cytomegalovirus (CMV). J Immunol Methods 130:209–216

Brown NA, Miller G (1982) Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein-Barr virus. J Immunol 128:24–29

Butler JL, Lane HC, Fauci AS (1983) Delineation of optimal conditions for producing mouse-human heterohybridomas from human peripheral blood B cells of immunized subjects. J Immunol 130:165–168

Carman WF, Traurwein C, van Deursen FJ, Colman K, Dorman E, McIntyre G, Waters J, Kliem V, Muller R, Thomas HC, Manns MP (1996) Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 24:489–493
Carroll WL, Thielemans K, Dilley J, Levy R (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 89:61–72
Casadevall A, Pirofski LA (2005) The potential of antibody-mediated immunity in the defense against biological weapons. Expert Opin Biol Ther 5:1359–1372
Casadevall A, Dadachova E, Pirofski LA (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695–703
Casali P, Inghirami G, Nakamura M, Davies TF, Notkins AL (1986) Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV. Science 234:476–479
CDC (1984) Postexposure prophylaxis of hepatitis B. Morb Mortal Wkly Rep 33:285–290
CDC (1985) Recommendations for protection against viral hepatitis. Morb Mortal Wkly Rep 34:313–324, 329–335
CDC (1996) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 45:1–36
CDC (1997a) MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch Ophthalmol 115:1528–1536
CDC (1997b) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 99:93–99
CDC (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531–537
CDC (2000) A new product (VarizIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 55:299–210
Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU (1993) A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol 151:7005–7015
Champion JM, Kean RB, Rupprecht CE, Notkins AL, Koprowski H, Dietzschold B, Hooper DC (2000) The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 235:81–90
Chiorazzi N, Wasserman RL, Kunkel HG (1982) Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas. J Exp Med 156:930–935
Cieplinski W, Reardon P, Testa MA (1983) Non-random human chromosome distribution in human-mouse myeloma somatic cell hybrids. Cytogenet Cell Genet 35:93–99
Cole SP, Campling BG, Louwman IH, Kozbor D, Roder JC (1984) A strategy for the production of human monoclonal antibodies reactive with lung tumor cell lines. Cancer Res 44:2750–2753
Colucci G, Kohzt DS, Waksal SD (1986) Preparation and characterization of human monoclonal antibodies directed against the hepatitis B virus surface antigen. Liver 6:145–152
Cote RJ, Morrissey DM, Houghton AN, Beattie EJ Jr, Oettgen HF, Old LJ (1983) Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci USA 80:2026–2030
Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921–1929
Croce CM, Linnenbach A, Hall W, Steplewski Z, Koprowski H (1980) Production of human hybridomas secreting antibodies to measles virus. Nature 288:488–489
Darveau A, Chevrier MC, Neron S, Delage R, Lemieux R (1993) Efficient preparation of human monoclonal antibody-secreting heterohybridomas using peripheral B lymphocytes cultured in the CD40 system. J Immunol Methods 159:139–143
Daugherty PS, Olsen MJ, Iverson BL, Georgiou G (1999) Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng 12:613–621

de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J (2006) A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58:359–368

Desgranges C, Paire J, Pichoud C, Souche S, Frommel D, Trepo C (1987) High affinity human monoclonal antibodies directed against hepatitis B surface antigen. J Virol Methods 16:281–292

Dessain SK, Adekar SP, Stevens JB, Carpenter KA, Skorski ML, Barnoski BL, Goldsby RA, Weinberg RA (2004) High efficiency creation of human monoclonal antibody-producing hybridomas. J Immunol Methods 291:109–122

DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr (2000) Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation—a compassionate use experience. Bone Marrow Transplant 25:161–165

Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M (2004) Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 77:1203–1208

Dietzschold B, Gore M, Casali P, Ueki Y, Rupprecht CE, Notkins AL, Koprowski H (1990) Biological characterization of human monoclonal antibodies to rabies virus. J Virol 64:3087–3090

Dorfman N, Dietzschold B, Kajiyama W, Fu ZF, Koprowski H, Notkins AL (1994) Development of human monoclonal antibodies to rabies. Hybridoma 13:397–402

Drobyksy WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schrau H, Magid P, Ehrlich P, Nadler PI, Ash RC (1991) Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 51:1190–1196

Ebeling SB, Bos HM, Slater R, Overkamp WJ, Cuthbert AP, Newbold RF, Zdzenicka MZ, Aarden LA (1998) Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. Cancer Res 58:2863–2868

Ehrlich PH, Moustafa ZA, Justice JC, Harfeldt KE, Kelley RL, Ostberg L (1992) Characterization of human monoclonal antibodies directed against hepatitis B surface antigen. Hum Antibodies Hybridomas 3:2–7

Eid AJ, Brown RA, Patel R, Razonable RR (2006) Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 43:40–48

Emanuel D, Gold J, Colacino J, Lopez C, Hammerling U (1984) A human monoclonal antibody to cytomegalovirus (CMV). J Immunol 133:2202–2205

Ensle K, Kurre R, Kohler R, Muller H, Kanzy EJ, Hilfenhaus J, Seiler FR (1991) A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 10:547–556

Ephrussi B, Weiss MC (1969) Hybrid somatic cells. Sci Am 220:26–35

Ergaz Z, Ornoy A (2006) Parvovirus B19 in pregnancy. Reprod Toxicol 21:421–435

Faller G, Vollmers HP, Weiglein I, Marx A, Zink C, Pfaff M, Muller-Hermelink HK (1990) HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies. Br J Cancer 62:595–598

Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE (2005) Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749–1759

Ferretti G, Merli M, Giannini Corradi S, Callejon V, Tansill P, Masini A, Ferretti S, Iappelli M, Rossi M, Rivarana D, Lilli D, Mancini C, Attili A, Berloco P (2004) Low-dose intramuscular hepatitis B globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36:535–538

Fiore AE, Wasley A, Bell BP (2006) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55:1–23
Foung S, Perkins S, Kafadar K, Gessner P, Zimmermann U (1990) Development of microfusion techniques to generate human hybridomas. J Immunol Methods 134:35–42
Foung SK, Perkins S, Raubitschek A, Larrick J, Lizak G, Fishwild D, Engleman EG, Grumet FC (1984) Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. J Immunol Methods 70:83–90
Foung SK, Perkins S, Koropchak C, Fishwild DM, Wittek AE, Engleman EG, Grumet FC, Arvin AM (1985) Human monoclonal antibodies neutralizing varicella-zoster virus. J Infect Dis 152:280–285
Foung SK, Perkins S, Bradshaw P, Rowe J, Rabin LB, Reyes GR, Lennette ET (1989) Human monoclonal antibodies to human cytomegalovirus. J Infect Dis 159:436–443
Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667
Gandhi MK, Khanna R (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4:725–738
Gebauer W, Lindl T (1990) Construction of human monoclonal antibodies against rabies NS-protein antigen by Epstein-Barr virus transformation. Arzneimittelforschung 40:718–722
Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES (2000) Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant 14:586–591
Ghany MG, Ayola B, Villanil FG, Gish RG, Rojter S, Vierling JM, Lok AS (1998) Hepatitis B virus mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213–222
Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey E (2000) Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 25:731–755
Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, Young NS, Zolla-Pazner S, Wolf H, Gorny MK, Modrow S (1999) Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 73:1974–1979
Gish RG, Cashland T (2006) Hepatitis B in liver transplant recipients. Liver Transpl 12: S54–S64
Goldsmith JC, Eller N, Mikolajczyk M, Manischewitz J, Golding H, Scott DE (2004) Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sang 86:125–129
Gray F, Kenney JS, Dunne JF (1995) Secretion capture and report web: use of affinity derivatized agarose microdroplets for the selection of hybridoma cells. J Immunol Methods 182:155–163
Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Koutermann RE, Jones PT, Low NM, Allison TJ, et al (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13:3245–3260
Grunow R, Jahn S, Porstmann T, Kiessling SS, Steinikellner H, Steindl F, Mattanovich D, Gurter L, Deinhardt F, Katier H, et al (1988) The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J Immunol Methods 106:257–265
Gustafsson B, Jondal M, Sundqvist VA (1991) SPAM-8, a mouse-human heteromyeloma fusion partner in the production of human monoclonal antibodies. Establishment of a human monoclonal antibody against cytomegalovirus. Hum Antibodies Hybridomas 2:26–32
Hadlock KG, Rowe J, Perkins S, Bradshaw P, Song GY, Cheng C, Yang J, Gascon R, Halmos J, Rehman SM, McGrath MS, Foung SK (1997) Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J Virol 71:5828–5840
Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74:10407–10416
Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231–243
Harris JF, Koropatnick J, Pearson J (1990) Spontaneous and radiation-induced genetic instability of heteromyeloma hybridoma cells. Mol Biol Med 7:485–493

Harris JF, Hawley RG, Hawley TS, Crawford-Sharpe GC (1992) Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J Immunol Methods 148:199–207

Hartmann G, Krieg AM (2000) Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164:944–953

Heijtink R, Paulij W, van Bergen P, van Roosmalen M, Rohm D, Eichentopf B, Muchmore E, de Man R, Osterhaus A (1999) In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. J Gen Virol 80:1529–1535

Heijtink RA, Kuuning J, Weber YA, de Man RA, Schalm SW (1995) Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an “inhibition in solution” assay. Hepatology 22:1078–1083

Henderson DA, Ingleby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterhaus A (1999) In vivo activity of a mixture of two human monoclonal antibodies in an “inhibition in solution” assay. Hepatology 30:1865–1874

Hollinger FB, Liang TJ (2001) Hepatitis B virus. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams and Wilkins, Philadelphia, pp 2971–3036

Holt SE, Glinsky VV, Ivanova AB, Glinsky GV (1999) Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog 25:241–248

Hooper JW, Custer DM, Thompson E (2003) Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181–195

Ichimori Y, Sasa K, Itoh H, Hitotsumachi S, Kimura Y, Kaneko K, Kida M, Tsukamoto K (1985) Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen. Biochem Biophys Res Commun 129:26–33

Ichimori Y, Harada K, Hitotsumachi S, Tsukamoto K (1987) Establishment of hybridomas secreting human monoclonal antibody against hepatitis B virus surface antigen. Biochem Biophys Res Commun 142:805–812

Ip HM, Leelie PN, Wong VC, Kuhns MC, Reesink HW (1989) Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1:406–410

Jessup CF, Baxendale H, Goldblatt D, Zola H (2000) Prevention of human-mouse heterohybridomas against an immunising antigen. J Immunol Methods 246:187–202

Kabir A, Alavian SM, Ahanchi N, Malekzadeh R (2006) Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res 36:265–271

Kalantarov GF, Rudchenko SA, Lobel L, Trakht I (2002) Development of a fusion partner cell line for efficient production of human monoclonal antibodies from peripheral blood lymphocytes. Hum Antibodies 11:85–96

Kang AS, Jones TM, Burton DR (1991) Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc Natl Acad Sci U S A 88:11120–11123

Kanzaki Y, Onoue F, Sakurai H, Ide T (2003) Telomerase upregulates expression levels of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor in normal human fibroblasts. Biochem Biophys Res Commun 305:150–154

Karlapar A, Dremucheva A, Czepulkowski BH (2001) A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci U S A 98:1799–1804

Keller MA, Steinh ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602–614
Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47:57–77
Schlom J, Wunderlich D, Teramoto YA (1980) Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci U S A 77: 6841–6845
Schmidt E, Leinfelder U, Gessner P, Zillikens D, Brocker EB, Zimmermann U (2001) CD19+ B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. J Immunol Methods 255:93–102
Sechet A, Bridoux F, Bauwens M, Ayache RA, Belmouaz S, Touchard G (2002) Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins. Transplant Proc 34:812–813
Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson L (1991) Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 183:16–22
Shirahata S, Kataoka Y, Teruya K (1998) Cell hybridization, hybridomas, and human hybridomas. Methods Cell Biol 57:111–145
Shulman M, Wilde CD, Kohler G (1978) A better cell line for making hybridomas secreting specific antibodies. Nature 276:269–270
Siemonet K, da Silva Cardoso M, Wolpl A, Koerner K, Subanek B (1994) Isolation and epitope characterization of human monoclonal antibodies to hepatitis C virus core antigen. Hybridoma 13:9–13
Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, Ushay HM, Sepkowitz KA (2002) Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 29:321–327
Smith GL, Vanderplasschen A, Law M (2002) The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83:2915–2931
Smith LL, Coller HA, Roberts JM (2003) Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 5:474–479
Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL Jr, Levey AS, et al (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317:1049–1054
Sokos DR, Berger M, Lazarus HM (2002) Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8:117–130
Stein LD, Sigal NH (1983) Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production. Cell Immunol 79:309–319
Stewart SA, Hahn WC, O’Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA (2002) Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99:12606–12611
Stricker EA, Tiebout RF, Lelie PN, Zeijlemaker WP (1985) A human monoclonal IgG1 lambda anti-hepatitis B surface antibody. Production, properties, and applications. Scand J Immunol 22:337–343
Sugano T, Matsumoto Y, Miyamoto C, Masuho Y (1987) Hybridomas producing human monoclonal antibodies against varicella-zoster virus. Eur J Immunol 17:359–364
Sugano T, Tomiyama T, Matsumoto Y, Sasaki S, Kimura T, Forghani B, Masuho Y (1991) A human monoclonal antibody against varicella-zoster virus glycoprotein III. J Gen Virol 72:2065–2073
Tan MP, Koren G (2006) Chickenpox in pregnancy: revisited. Reprod Toxicol 21:410–420
Terrault NA, Vyas G (2003) Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 7:537–550
Terrault NA, Zhou S, McCory RW, Pruitt TL, Lake JR, Roberts JP, Ascher NL, Wright TL (1998) Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28:555–561
Exploring the Native Human Antibody Repertoire

Thompson JM, Lowe J, McDonald DF (1994) Human monoclonal anti-D secreting heterohybridomas from peripheral B lymphocytes expanded in the CD40 system. J Immunol Methods 175:137–140

Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179–186

Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE Jr (2007) Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory B cells. Mol Immunol 44:2173–2183

Tiebout RF, van Bokxel-Oosterhof F, Stricker EA, Zeijlemaker WP (1987) A human hybrid hybridoma. J Immunol 139:3402–3405

Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875

Ueki Y, Goldfarb IS, Harindranath N, Gore M, Kropowski H, Notkins AL, Casali P (1990) Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 171:19–34

Vaisbourd M, Ignatovich O, Dremucheva A, Karpas A, Winter G (2001) Molecular characterization of human monoclonal antibodies derived from fusions of tonsil lymphocytes with a human myeloma cell line. Hybrid Hybridomics 20:287–292

Varga M, Remport A, Hidvegi M, Peter A, Kobori L, Telkes G, Fazakas J, Gerlei Z, Sarvary E, Sulyok B, Jaray J (2005) Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience. Transpl Infect Dis 7:63–67

Welliver RC (2003) Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 22: S6–S10; discussion S10–S12

Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433–455

Xiao XM, Li AZ, Chen X, Zhu YK, Miao J (2007) Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet 96:167–170

Xu JL, Davis MM (2000) Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13:37–45

Xu Q, Xiao L, Lu XB, Zhang YX, Cai X (2006) A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol 12:3434–3437

Yoshinari K, Arai K, Kimura H, Matsumoto K, Yamaguchi Y (1996) Efficient production of IgG human monoclonal antibodies by lymphocytes stimulated by lipopolysaccharide, pokeweed mitogen, and interleukin 4. In Vitro Cell Dev Biol Anim 32:372–377

Young J (2002) Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 96 [Suppl B]: S31–35

Zhu Y, Jin B, Sun C, Huang C, Liu X (1993) The effects of hybridoma growth factor in conditioned media upon the growth, cloning, and antibody production of heterohybridoma cell lines. Hum Antibodies Hybridomas 4:31–35

Zhu Y, Jin B, Jiang S, Sun K, Sun C, Liu X (1999) Improved fusion partners transfected with DNA fragment encoding IL-11 on generation of human B lymphocyte hybridomas. Hum Antibodies 9:1–7

Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A (1998) A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytoengalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83:132–137